Home › Funds › Blue Owl Capital Holdings LP › VRDN

Blue Owl Capital Holdings LP position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Blue Owl Capital Holdings LP reported holding 1,582,767 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$22.4M, representing 4.22% of its reported portfolio and ranking #7 among its reported holdings. Blue Owl Capital Holdings LP has disclosed VRDN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)1.58M sh
Reported value held$22.42M
Portfolio Weight4.22%
First reportedQ2 2026
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Blue Owl Capital Holdings LP's VRDN position evolved

Blue Owl Capital Holdings LP first disclosed a stake in VRDN in Q2 2026 at 260,000 shares (US$4.8M). The position peaked in Q3 2026 at 1,582,767 shares, worth US$22.4M. Across 2 filings, Blue Owl Capital Holdings LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,582,767 shares valued at US$22.4M — an increase of 1,322,767 shares quarter over quarter.. Notable position changes include a 509% increase in Q3 2026 (shares rose 52% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 260.00K $4.78M New
Q3 2026 1.58M $22.42M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Blue Owl Capital Holdings LP held VRDN?

Blue Owl Capital Holdings LP has disclosed VRDN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Blue Owl Capital Holdings LP's current position in VRDN?

As of Q3 2026, Blue Owl Capital Holdings LP holds 1.58M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $22.42M, representing 4.22% of its reported portfolio and ranking #7.

Has Blue Owl Capital Holdings LP been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Blue Owl Capital Holdings LP increased its position in VRDN. The position peaked in Q3 2026 at 1.58M shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.